Almirall’s Tudorza Pressair aclidinium bromide dry powder inhaler for the maintenance treatment of COPD is now available in the United States, where it is being marketed by Forest Laboratories. The twice-daily anticholinergic was approved in July 2012, as were the European versions of the product, the Eklira and Bretaris Genuair DPIs.
Forest and Almirall will co-promote an aclidinium inhaler in Canada, where Almirall recently established a presence. Almirall will promote the product itself in the rest of the world.
Read the Forest and Almirall press release.
